AMGN - Amgen Inc.
195.24 -0.23 (-0.12%)
Pre-Market: 8:12AM EDT
| Previous Close | 194.00 |
| Open | 194.41 |
| Bid | 190.61 x 900 |
| Ask | 195.21 x 800 |
| Day's Range | 194.33 - 196.66 |
| 52 Week Range | 166.30 - 211.90 |
| Volume | 2,428,846 |
| Avg. Volume | 3,182,452 |
| Market Cap | 117.224B |
| Beta (3Y Monthly) | 0.80 |
| PE Ratio (TTM) | 15.52 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 5.80 (2.99%) |
| Ex-Dividend Date | 2019-08-14 |
| 1y Target Est | N/A |
- Zacks
Vertex Gains Reimbursement for Orkambi & Symkevi in Scotland
Vertex (VRTX) secures reimbursement nods in Scotland for its cystic fibrosis drugs Orkambi and Symkevi.
- Zacks
Celgene's (CELG) Leukemia Candidate Meets Endpoints in Study
Celgene's (CELG) CC-486 maintenance therapy improves overall survival in newly-diagnosed acute myeloid leukemia patients.
- Zacks
The Zacks Analyst Blog Highlights: Amgen, Cisco, Berkshire Hathaway, T. Rowe Price and McKesson
The Zacks Analyst Blog Highlights: Amgen, Cisco, Berkshire Hathaway, T. Rowe Price and McKesson
- Zacks
REGENXBIO (RGNX) Catches Eye: Stock Jumps 5.8%
REGENXBIO (RGNX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
- Investor's Business Daily
Amgen Stock Is The Biggest Biotech Stock, But Should You Buy It?
Shares of Amgen are on an upswing after winning a patent battle over its drug Enbrel against Novartis subsidiary Sandoz. Is it time to buy shares of the massive biotech company?
- American City Business Journals
2019 BusinessWoman of the Year honoree: Jaclyn Schuler
Jaclyn Schuler’s role as a leader at Amgen in Tampa is to motivate her teams to deliver value and impact the bottom line.
- Zacks
Top Research Reports for Amgen, Cisco & Berkshire Hathaway
Top Research Reports for Amgen, Cisco & Berkshire Hathaway
- Zacks
Puma Biotech's sNDA for Nerlynx Combo Gets FDA Acceptance
The FDA accepts for review Puma Biotech's (PBYI) sNDA that seeks an approval for Nerlynx in combination with Roche's Xeloda for treating third-line breast cancer.
- Zacks
Ultragenyx to Submit sBLA for Label Expansion of Crysvita
Ultragenyx (RARE) and partner Kyowa Kirin plan to submit an sBLA to the FDA for the label expansion of Crysvita.
- Zacks
Biotech Stock Roundup: AMGN's Lung Cancer Candidate, ALXN's Deal With Eidos in Focus
Key highlights of the past week include regulatory and pipeline updates, and licensing deals and more.
- Investor's Business Daily
Is Nancy Pelosi's Drug-Pricing Plan Feasible — Or Is It A Political Ploy?
Shares of pharmaceutical companies toppled Tuesday on reports the House of Representatives will release a plan that allows the federal government to negotiate drug prices in Medicare.
- Zacks
Alexion (ALXN) In-licenses Amyloidosis Candidate In Japan
Alexion (ALXN) strengthens its amyloidosis portfolio with an exclusive license secured from Eidos to develop and commercialize an investigational small molecule AG10 in Japan.
- Zacks
Adaptimmune (ADAP) Gets Orphan Drug Status for T-cell Therapy
Adaptimmune Therapeutics (ADAP) gets Orphan Drug Designation for SPEAR T-cells targeting MAGE-A4 (ADP-A2M4 program) for the treatment of soft tissue sarcomas.
- Zacks
Horizon's (HZNP) Eye Disease Drug Gets FDA's Priority Review
Horizon (HZNP) announces the FDA has accepted the Biologics License Application (BLA) for teprotumumab, for the treatment of active thyroid eye disease, and granted it Priority Review designation.
- Investing.com
Amgen Falls 3%
Investing.com - Amgen (NASDAQ:AMGN) fell by 3.16% to trade at $195.92 by 10:53 (14:53 GMT) on Tuesday on the NASDAQ exchange.
- Investor's Business Daily
Amgen Stock Dives On Lackluster Cancer Test — But There's A Bright Side
Amgen stock toppled Monday after the biotech company's experimental cancer treatment failed to impress investors in a Phase 1 study. The drug attempts to inhibit a protein known as KRAS.
- Reuters
US STOCKS-Tech, healthcare weigh on Wall Street, stimulus hopes flicker
Microsoft Corp and Amgen Inc were among the biggest drags on the S&P 500 and Nasdaq. Amgen fell 3.19% after analysts raised questions about data on the company's lung cancer drug, dragging the healthcare sector down 0.94%. Financial stocks rose 1.20%, providing the biggest boost to the S&P 500, with banks gaining 2.62%.
- Zacks
Novartis Announces Positive Long-Term Data on Migraine Drug
Novartis' (NVS) migraine drug Aimovig is effective and safe in treating patients with episodic migraine in a long-term study.
- Benzinga
Amgen's KRAS Inhibitor Shows Lukewarm Response In Lung Cancer Study
Amgen said in a Sunday statement that new data from the Phase 1 study of AMG 510 presented as an oral presentation at the IASLC 2019 World Conference on Lung Cancer, or WCLC, showed that out of the 13 of the evaluable patients receiving the target dose of 960mg once daily — the highest dose — seven, or 54%, achieved a partial response at one or more timepoints and six achieved stable disease. Nine of the 13 patients are continuing to take the daily pill, Amgen said. Of the partial responders, two died and another quit the study due to disease progression.
- TheStreet.com
[video]Eli Lilly's Must-Hold Level on Drug-Data Pullback
Eli Lilly stock is falling on the day after releasing clinical trial data. Here's the must-hold spot for LLY stock now.
- Zacks
Amgen's KRAS Inhibitor Shows Response in Larger NSCLC Group
Amgen's (AMGN) novel investigational KRAS inhibitor, AMG 510, for solid tumor shows anti-tumor activity in a larger group of NSCLC patients.
- Barrons.com
Amgen Stock Is Falling as Cancer-Drug Report Fails to Impress Investors
New data on a key drug in Amgen’s cancer pipeline sent shares of the company down 3.6% in premarket trading on Monday, though the company said it remained enthusiastic about the promise of the drug.
- Yahoo Finance Video
Amgen shares fall after lung cancer drug misses forecasts
Yahoo Finance's Dan Roberts, Sibile Marcellus, and Julia La Roche discuss Amgen's falling stock after it's key lung cancer drug missed Wall Street forecasts.
- Yahoo Finance Video
Nissan's CEO to step down September 15th, Elliot Management takes $3.2B stake in AT&T
Nissan CEO, Hiroto Saikawa, is stepping down September 15th after a controversial term. Meanwhile, Elliot Management takes a $3.2B stake in AT&T, Amgen's drug trial came in short of Wall Street expectations and Amazon is set to hold a nationwide career day on September 17th. Yahoo Finance's Ines Ferre breaks down the details from the New York Stock Exchange.
![[video]Eli Lilly's Must-Hold Level on Drug-Data Pullback](https://s.yimg.com/uu/api/res/1.2/Wo8w1uQ28AlgKkPKPeQqKA--~B/Zmk9c3RyaW07aD0xMjM7cHlvZmY9MDtxPTgwO3c9MjIwO3NtPTE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/thestreet.com/287e582de04a5b0373db2b1a6089c045)
